More notable recent Astellas Pharma Inc. (OTCMKTS:ALPMF) news were published by: Prnewswire.com which released: “Astellas Pharma Chooses Verizon Secure Cloud Interconnect to Centralize Global …” on December 06, 2017, also Prnewswire.com with their article: “Astellas Acquires Mitobridge Under Existing Collaboration” published on December 01, 2017, Prnewswire.com published: “Astellas Announces First Clinical Data from Phase I Study of Gilteritinib in …” on December 11, 2017. More interesting news about Astellas Pharma Inc. (OTCMKTS:ALPMF) were released by: Prnewswire.com and their article: “Astellas Appoints João Carlos de Britto as General Manager of Astellas Farma …” published on December 04, 2017 as well as Prnewswire.com‘s news article titled: “Astellas to Present New Data Exploring Gilteritinib in Newly Diagnosed Acute …” with publication date: November 28, 2017.
Astellas Pharma Inc., a pharmaceutical company, makes, markets, and imports and exports pharmaceutical products worldwide. The company has market cap of $25.55 billion. The firm offers Prograf and Advagraf/Graceptor/ASTAGRAF XL/Prograf XL, an immunosuppressant used to suppress organ transplant rejection; Vesicare, a treatment for overactive bladder; Harnal/Omnic, a blocking agent to treat the functional symptoms of benign prostatic hyperplasia; and Funguard/MYCAMIN, a candin-type antifungal agent. It has a 16.04 P/E ratio. It also provides Geninax, an oral new-type quinolone antibacterial agent; Celecox, an anti-inflammatory agent; Lipitor, a treatment for hypercholesterolemia; Micardis/Micombi/Micamlo, a treatment for hypertension; Gaster, a treatment for peptic ulcer and gastritis; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic agonist indicated for the treatment of overactive bladder; Eligard, a luteinizing hormone-releasing hormone agonist for the treatment of prostate cancer; XTANDI for the treatment of prostate cancer; and VESOMNI, a release tablet for the treatment of moderate to severe storage symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not adequately responding to treatment with monotherapy.
みなさん こんばんわ
海外サイト見てましたら・・こんなん記事が・・
翻訳システムで検索してみてください。 では・・
More notable recent Astellas Pharma Inc. (OTCMKTS:ALPMF) news were published by: Prnewswire.com which released: “Astellas Pharma Chooses Verizon Secure Cloud Interconnect to Centralize Global …” on December 06, 2017, also Prnewswire.com with their article: “Astellas Acquires Mitobridge Under Existing Collaboration” published on December 01, 2017, Prnewswire.com published: “Astellas Announces First Clinical Data from Phase I Study of Gilteritinib in …” on December 11, 2017. More interesting news about Astellas Pharma Inc. (OTCMKTS:ALPMF) were released by: Prnewswire.com and their article: “Astellas Appoints João Carlos de Britto as General Manager of Astellas Farma …” published on December 04, 2017 as well as Prnewswire.com‘s news article titled: “Astellas to Present New Data Exploring Gilteritinib in Newly Diagnosed Acute …” with publication date: November 28, 2017.
Astellas Pharma Inc., a pharmaceutical company, makes, markets, and imports and exports pharmaceutical products worldwide. The company has market cap of $25.55 billion. The firm offers Prograf and Advagraf/Graceptor/ASTAGRAF XL/Prograf XL, an immunosuppressant used to suppress organ transplant rejection; Vesicare, a treatment for overactive bladder; Harnal/Omnic, a blocking agent to treat the functional symptoms of benign prostatic hyperplasia; and Funguard/MYCAMIN, a candin-type antifungal agent. It has a 16.04 P/E ratio. It also provides Geninax, an oral new-type quinolone antibacterial agent; Celecox, an anti-inflammatory agent; Lipitor, a treatment for hypercholesterolemia; Micardis/Micombi/Micamlo, a treatment for hypertension; Gaster, a treatment for peptic ulcer and gastritis; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic agonist indicated for the treatment of overactive bladder; Eligard, a luteinizing hormone-releasing hormone agonist for the treatment of prostate cancer; XTANDI for the treatment of prostate cancer; and VESOMNI, a release tablet for the treatment of moderate to severe storage symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not adequately responding to treatment with monotherapy.